GSK has posted a string of drug trial wins lately. Its specialty medicines division saw strong growth in Q3, with sales up 19%. HIV treatments climbed 12%, and oncology revenue surged 94%.

GSK plc's stock downgraded from “Buy” to “Hold” due to litigation risks, disappointing RSV vaccine sales, and competitive pressures in the HIV space. Despite strong cash flow, GSK's Zantac ...

Starting with Z – the antacid, Zantac In early October, Glaxo Smith Kline (GSK) settled 83% of its remaining Zantac cases, some 80,000 claims, for $2.2 billion. Simultaneously, they announced a ...

An earlier case against Zantac brought in December 2022 by some 50,000 plaintiffs at a pre-trial federal court hearing in Florida was dismissed.

Delaware’s top court ruled in GSK’s favor in saying it will review the admissibility of expert evidence in an upcoming trial over possible cancer risks from its Zantac heartburn remedy ...

Delaware’s top court ruled in GSK’s favor in saying it will review the admissibility of expert evidence in an upcoming trial over possible cancer risks from its Zantac heartburn remedy ...

GSK is currently being sued by nearly 75,000 plaintiffs in the state of Delaware over claims its Zantac heartburn remedy increases the risk of users developing ten separate cancers including liver ...

Zantac, once one of the world's best-selling drugs, is now at the center of a massive legal battle. For decades, its manufacturer, Glaxo (now GlaxoSmithKline or GSK), allegedly concealed the ...

UK-based GlaxoSmithKline PLC (GB:GSK) has won the latest U.S. trial concerning its heartburn drug Zantac (ranitidine), amid litigation over alleged cancer risks. The Florida State Court ruled in ...

GSK Wins Zantac Cancer Lawsuit in Florida Provided by Dow Jones Aug 16, 2024, 12:38:00 AM ...

A jury in an Illinois state court has found that UK drugmaker GSK (LSE: GSK) is not liable for causing a plaintiff’s colorectal cancer. This marks the latest legal win for GSK against claims that the ...